BRPI0913297B8 - composição farmacêutica estabilizada - Google Patents

composição farmacêutica estabilizada

Info

Publication number
BRPI0913297B8
BRPI0913297B8 BRPI0913297A BRPI0913297A BRPI0913297B8 BR PI0913297 B8 BRPI0913297 B8 BR PI0913297B8 BR PI0913297 A BRPI0913297 A BR PI0913297A BR PI0913297 A BRPI0913297 A BR PI0913297A BR PI0913297 B8 BRPI0913297 B8 BR PI0913297B8
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical composition
stabilized pharmaceutical
compositions
generally
Prior art date
Application number
BRPI0913297A
Other languages
English (en)
Inventor
Brumfield Jay
Freehauf Keith
Tully Roger
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BRPI0913297A2 publication Critical patent/BRPI0913297A2/pt
Publication of BRPI0913297B1 publication Critical patent/BRPI0913297B1/pt
Publication of BRPI0913297B8 publication Critical patent/BRPI0913297B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição farmacêutica ,uso de uma composiçã, e, kit terapêutico. esta invenção refere-se às composições (por exemplo, composições auriculares) compreendendo um antibiótico (geralmente uma quinolona ou naftiridinona), corticosteróide, e ácido orgânico (geralmente um ácido graxo). esta invenção também se refere aos métodos de tratamento usando uma tal composição, o uso de uma tal composição para produzir medicamentos, e kits terapêuticos compreendendo uma tal composição.
BRPI0913297A 2008-06-02 2009-06-02 composição farmacêutica estabilizada BRPI0913297B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5794008P 2008-06-02 2008-06-02
PCT/EP2009/056751 WO2009147144A2 (en) 2008-06-02 2009-06-02 Composition comprising an antibiotic and a corticosteroid

Publications (3)

Publication Number Publication Date
BRPI0913297A2 BRPI0913297A2 (pt) 2016-01-26
BRPI0913297B1 BRPI0913297B1 (pt) 2019-01-29
BRPI0913297B8 true BRPI0913297B8 (pt) 2020-09-15

Family

ID=41278754

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913297A BRPI0913297B8 (pt) 2008-06-02 2009-06-02 composição farmacêutica estabilizada

Country Status (13)

Country Link
US (2) US20100087409A1 (pt)
EP (1) EP2293778B1 (pt)
JP (1) JP5674648B2 (pt)
CN (1) CN102083414B (pt)
AR (1) AR071988A1 (pt)
AU (1) AU2009253956B2 (pt)
BR (1) BRPI0913297B8 (pt)
CA (1) CA2726074C (pt)
ES (1) ES2436193T3 (pt)
HK (1) HK1156876A1 (pt)
RU (1) RU2496501C2 (pt)
TW (1) TW201010708A (pt)
WO (1) WO2009147144A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084445B2 (en) * 2004-08-13 2011-12-27 Schering-Plough Animal Health Corporation Pharmaceutical formulation
WO2012087280A2 (en) 2010-12-20 2012-06-28 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
EP2502616A1 (fr) * 2011-03-21 2012-09-26 Matthew Krayenbuhl Composition pharmaceutique nasale
AU2013208252B2 (en) * 2012-01-10 2016-03-03 Entrx LLC Otic formulations, methods and devices
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations
MX2018015475A (es) * 2016-06-13 2019-07-12 Vyome Therapeutics Ltd Composiciones antifungicas sinérgicas y métodos de las mismas.
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
CA2111003A1 (en) * 1991-06-10 1992-12-23 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
US7917386B2 (en) * 1995-06-16 2011-03-29 Catalina Marketing Corporation Virtual couponing method and apparatus for use with consumer kiosk
US5710886A (en) * 1995-06-16 1998-01-20 Sellectsoft, L.C. Electric couponing method and apparatus
GB9620187D0 (en) * 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
EP1179002A4 (en) * 1999-05-07 2002-08-07 Smithkline Beecham Corp METHODS USING MECHANISMS OF ACTION OF AROA
US20080052169A1 (en) * 2000-03-29 2008-02-28 O'shea Deirdre Method and apparatus for providing a coupon offer having a variable value
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
US6589955B2 (en) * 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
WO2003025822A1 (en) * 2001-09-19 2003-03-27 Matsushita Electric Corporation Of America Adaptive electronic coupon
RU2267491C1 (ru) * 2004-07-14 2006-01-10 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Физиологически активная композиция, замещенные 1-оксо-1,2-дигидро[2,7]-нафтиридины, способ их получения, применения и набор
KR101091461B1 (ko) * 2003-11-07 2011-12-07 센주 세이야꾸 가부시키가이샤 프로스타글란딘 함유 의약 조성물
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US8084445B2 (en) * 2004-08-13 2011-12-27 Schering-Plough Animal Health Corporation Pharmaceutical formulation
US20060041469A1 (en) * 2004-08-18 2006-02-23 Torrance Mathis Marketing system employing electronically generated discount coupons
CA2631757A1 (en) * 2005-12-02 2007-06-07 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
US20070196398A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone fatty acid salt compositions
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas

Also Published As

Publication number Publication date
RU2496501C2 (ru) 2013-10-27
CN102083414A (zh) 2011-06-01
TW201010708A (en) 2010-03-16
CN102083414B (zh) 2013-10-23
RU2010154083A (ru) 2012-07-20
HK1156876A1 (en) 2012-06-22
BRPI0913297A2 (pt) 2016-01-26
BRPI0913297B1 (pt) 2019-01-29
AR071988A1 (es) 2010-07-28
WO2009147144A3 (en) 2010-09-16
CA2726074A1 (en) 2009-12-10
JP5674648B2 (ja) 2015-02-25
WO2009147144A2 (en) 2009-12-10
ES2436193T3 (es) 2013-12-27
AU2009253956B2 (en) 2016-05-12
AU2009253956A1 (en) 2009-12-10
CA2726074C (en) 2016-07-19
JP2011521999A (ja) 2011-07-28
US10045940B2 (en) 2018-08-14
US20100087409A1 (en) 2010-04-08
EP2293778A2 (en) 2011-03-16
EP2293778B1 (en) 2013-09-18
US20120046259A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
BRPI0913297B8 (pt) composição farmacêutica estabilizada
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BRPI0514407A (pt) forma ii de polimorfo de rapamicina, processos para preparar a forma ii do polimorfo de rapaminicina, e a forma i do polimorfo de rapamicina, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica
EA201000774A1 (ru) Ингибиторы бета-лактамазы
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BRPI0915084B8 (pt) composto, e, composição farmacêutica
NO20084334L (no) Farmasoytiske sammensetninger
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
EA201170832A1 (ru) Пуриновые соединения
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
MX2011009847A (es) Agentes antihelminticos y su uso.
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2009, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2508 DE 29/01/2019 QUANTO AO TITULAR E AO ENDERECO.